Fortress Biotech (Fortress Biotech) Interest Expense : $-11.91 Mil (TTM As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Fortress Biotech Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Fortress Biotech's interest expense for the three months ended in Dec. 2023 was $ -1.52 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-11.91 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Fortress Biotech's Operating Income for the three months ended in Dec. 2023 was $ -22.76 Mil. Fortress Biotech's Interest Expense for the three months ended in Dec. 2023 was $ -1.52 Mil. Fortress Biotech did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Fortress Biotech Interest Expense Historical Data

The historical data trend for Fortress Biotech's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fortress Biotech Interest Expense Chart

Fortress Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-8.53

-9.70

-11.39

-10.42

-11.92

Fortress Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-3.02	-3.32	-5.20	-1.88	-1.52

Fortress Biotech Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.91 Mil.

Fortress Biotech (NAS:FBIO) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Fortress Biotech's Interest Expense for the three months ended in Dec. 2023 was $-1.52 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-22.76 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $79.14 Mil.

Fortress Biotech's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Fortress Biotech did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Fortress Biotech (Fortress Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortress Biotech Inc (NAS:FBIO) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

FBIOP.PFD:USA CNB0.PFD:Germany

Address

1111 Kane Concourse, Suite 301, Bay Harbor Island, FL, USA, 33154

Website

https://www.fortressbiotech.com

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.

Executives

Rosenwald Lindsay A Md	director, 10 percent owner, officer: PRESIDENT, CEO & CHAIRMAN	375 PARK AVE, NEW YORK NY 10152
Lucy Lu	director	THE FEMALE HEALTH COMPANY, 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
David Jin	officer: Chief Financial Officer	C/O AVENUE THERAPEUTICS, INC., 1140 AVENUE OF THE AMERICAS, FLOOR 9, NEW YORK NY 10036
Dov Klein	director	C/O FORTRESS BIOTECH, INC., 3 COLUMBUS CIRCLE, 15TH FLOOR, NEW YORK NY 10019
Robyn Hunter	officer: Chief Financial Officer	95 SAWYER ROAD, SUITE 110, WALTHAM MA 02453
Eric K Rowinsky	director	IMCLONE SYSTEMS INCORPORATED, 180 VARICK STREET, 6TH FLOOR, NEW YORK NY 10014
Malcolm Hoenlein	director	750 LEXINGTON AVENUE, NEW YORK NY 10022
Michael S Weiss	director, 10 percent owner, officer: EXECUTIVE VICE CHAIRMAN	750 LEXINGTON AVE, NEW YORK NY 10022
J Jay Lobell	director	365 W END AVE, APARTMENT 10A, NEW YORK NY 10024
Jimmie Harvey	director	3741 EAST FAIRWAY DRIVE, BIRMINGHAM AL 35213
Kevin Lorenz	director	C/O NUVEEN, 333 W. WACKER DR., CHICAGO IL 60606
George Avgerinos	officer: SVP, Biologics Operations	C/O CORONADO BIOSCIENCES, INC., 24 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Kevin Horgan	other: Former Chief Medical Officer	C/O SOLIGENIX, INC., 29 EMMONS DRIVE, STE. C-10, PRINCETON NJ 08540
David Jonathan Barrett	director	ONE PENN PLAZA, SUITE 2514, NEW YORK NY 10119
Harlan F Weisman	director	C/O CORONADO BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803